{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:30:20Z","timestamp":1786512620023,"version":"build-2736575974"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Rheumatoid arthritis (RA) affects approximately 1% of the global population and is the most common inflammatory arthritis in adults. RA is well established as a significant risk factor for secondary osteoporosis (OP). Bone loss in RA occurs at three anatomically distinct levels: periarticular osteopenia, marginal erosions at the joint periphery, and generalised systemic OP. Understanding the complex mechanism underlying osteoclast-mediated bone loss in RA is essential for the development of targeted interventions, while identification of individuals at risk of OP and fracture remains paramount. This review will highlight recent advances in these areas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>The cornerstone of bone loss management and prevention in RA remains disease activity control and reduction of inflammation. In this review, we will discuss the most recent advances in understanding the mechanism of bone loss in RA, the skeletal effects of current RA and anti-OP therapies in the RA population. We also highlight areas where future research may be focused to inform best management of bone health in these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>RA associated bone loss remains a substantial contributor to morbidity, highlighting the need for improved fracture risk stratification, optimisation of therapeutic approaches, and greater standardisation of monitoring strategies. Critical evidence gaps persist, including the absence of validated RA specific fracture risk thresholds to guide treatment decisions and the lack of prospective randomised trials comparing bone protective agents in RA associated osteoporosis. Data in men with RA remain limited, and further work is required to delineate the relative skeletal effects of biologic therapies. Additionally, optimal DXA monitoring intervals for patients with stable disease on DMARD therapy are not well defined, contributing to considerable variation in clinical practice. Addressing these unmet needs will be essential to advancing bone health management and reducing fracture burden in individuals with RA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11926-026-01230-2","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T02:57:33Z","timestamp":1786503453000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bone Health in Rheumatoid Arthritis: An Update"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8481-6343","authenticated-orcid":false,"given":"Faidra","family":"Laskou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Dennison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"issue":"1","key":"1230_CR1","doi-asserted-by":"publisher","first-page":"10736","DOI":"10.1038\/s41598-025-92150-1","volume":"15","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Gao X, Liu S, Wang Q, Wang Y, Hou S, et al. Global, regional, and national epidemiology of rheumatoid arthritis among people aged 20\u201354 years from 1990 to 2021. Sci Rep. 2025;15(1):10736.","journal-title":"Sci Rep"},{"issue":"1","key":"1230_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s41927-025-00520-z","volume":"9","author":"VJ Vera-Ponce","year":"2025","unstructured":"Vera-Ponce VJ, Ballena-Caicedo J, Zuzunaga-Montoya FE, Loayza-Castro JA, Valladolid-Sandoval LAM, V\u00e1squez-Romero LEM, et al. Prevalence of osteoporosis in chronic diseases: an umbrella review of 283 observational studies from 13 systematic reviews. BMC Rheumatol. 2025;9(1):66.","journal-title":"BMC Rheumatol"},{"issue":"15","key":"1230_CR3","doi-asserted-by":"publisher","first-page":"8740","DOI":"10.3390\/ijms23158740","volume":"23","author":"P Pietschmann","year":"2022","unstructured":"Pietschmann P, Butylina M, Kerschan-Schindl K, Sipos W. Mechanisms of systemic osteoporosis in rheumatoid arthritis. Int J Mol Sci. 2022;23(15):8740.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1230_CR4","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1007\/s10067-022-06212-0","volume":"41","author":"J Qiu","year":"2022","unstructured":"Qiu J, Lu C, Zhang L, Zhou X, Zou H. Osteoporosis in patients with rheumatoid arthritis is associated with serum immune regulatory cellular factors. Clin Rheumatol. 2022;41(9):2685\u201393.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"1230_CR5","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s00198-021-05824-7","volume":"32","author":"N Guanabens","year":"2021","unstructured":"Guanabens N, Olmos JM, Hernandez JL, Cerda D, Hidalgo Calleja C, Martinez Lopez JA, et al. Vertebral fractures are increased in rheumatoid arthritis despite recent therapeutic advances: a case-control study. Osteoporos Int. 2021;32(7):1333\u201342.","journal-title":"Osteoporos Int"},{"key":"1230_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2147\/OARRR.S318810","volume":"13","author":"A Abdulkhaliq","year":"2021","unstructured":"Abdulkhaliq A, Cheikh M, Almuntashri F, Alzahrani H, Nadwi H, Kadi E, et al. A Comparison of Demographics, Disease Activity, Disability, and Treatment Among Rheumatoid Arthritis Patients with and without Osteoporosis. Open Access Rheumatol. 2021;13:275\u201383.","journal-title":"Open Access Rheumatol"},{"key":"1230_CR7","doi-asserted-by":"publisher","first-page":"962969","DOI":"10.3389\/fmed.2022.962969","volume":"9","author":"R Sakthiswary","year":"2022","unstructured":"Sakthiswary R, Uma Veshaaliini R, Chin KY, Das S, Sirasanagandla SR. Pathomechanisms of bone loss in rheumatoid arthritis. Front Med (Lausanne). 2022;9:962969.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"1230_CR8","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.3390\/ijms23052871","volume":"23","author":"K Maeda","year":"2022","unstructured":"Maeda K, Yoshida K, Nishizawa T, Otani K, Yamashita Y, Okabe H, et al. Inflammation and bone metabolism in rheumatoid arthritis: Molecular mechanisms of joint destruction and pharmacological treatments. Int J Mol Sci. 2022;23(5):2871.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1230_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11657-022-01061-5","volume":"17","author":"CL Gregson","year":"2022","unstructured":"Gregson CL, Armstrong DJ, Bowden J, Cooper C, Edwards J, Gittoes NJL, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2022;17(1):58.","journal-title":"Arch Osteoporos"},{"issue":"7","key":"1230_CR10","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/imj.70065","volume":"55","author":"A Lyon","year":"2025","unstructured":"Lyon A, Lester S, Stanhope J, Lynch T, Black R, Barrett C, et al. Dual-energy X-ray absorptiometry and anti-osteoporotic medication use in Australian patients with early rheumatoid arthritis using data from the Australian Rheumatology Association Database. Intern Med J. 2025;55(7):1127\u201335.","journal-title":"Intern Med J"},{"issue":"7","key":"1230_CR11","doi-asserted-by":"publisher","first-page":"e096226","DOI":"10.1136\/bmjopen-2024-096226","volume":"15","author":"C Cho","year":"2025","unstructured":"Cho C, Bak G, Richards B, Sherrington C. Epidemiology and factors associated with osteoporosis, falls and fractures in patients with chronic inflammatory rheumatic disease: a scoping review. BMJ Open. 2025;15(7):e096226.","journal-title":"BMJ Open"},{"issue":"6","key":"1230_CR12","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.ard.2026.01.023","volume":"85","author":"JS Smolen","year":"2026","unstructured":"Smolen JS, Edwards CJ, Konzett V, Laskou F, Aletaha D, Caporali R, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. Ann Rheum Dis. 2026;85(6):991\u20131009.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1230_CR13","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.3390\/jcm9103361","volume":"9","author":"P Le Fardellone","year":"2020","unstructured":"Fardellone P, Salawati E, Le Monnier L, Goeb V. Bone loss, osteoporosis, and fractures in patients with rheumatoid arthritis: a review. J Clin Med. 2020;9(10):3361.","journal-title":"J Clin Med"},{"issue":"9","key":"1230_CR14","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1002\/jbmr.2286","volume":"29","author":"N Harvey","year":"2014","unstructured":"Harvey N, Dennison E, Cooper C, Osteoporosis. A Lifecourse Approach. J Bone Miner Res. 2014;29(9):1917\u201325.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"1230_CR15","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s43556-025-00349-5","volume":"6","author":"X Zhang","year":"2025","unstructured":"Zhang X, Liang Y, Zhang F, Liu X. Osteoporosis: molecular pathogenesis and therapeutic interventions. Mol Biomed. 2025;6(1):98.","journal-title":"Mol Biomed"},{"key":"1230_CR16","doi-asserted-by":"publisher","first-page":"601618","DOI":"10.3389\/fmed.2020.601618","volume":"7","author":"I Llorente","year":"2020","unstructured":"Llorente I, Garcia-Castaneda N, Valero C, Gonzalez-Alvaro I, Castaneda S. Osteoporosis in Rheumatoid Arthritis: Dangerous Liaisons. Front Med (Lausanne). 2020;7:601618.","journal-title":"Front Med (Lausanne)"},{"key":"1230_CR17","doi-asserted-by":"publisher","first-page":"1643285","DOI":"10.3389\/fmed.2025.1643285","volume":"12","author":"Y Wei","year":"2025","unstructured":"Wei Y, Xie X, Li D, Hou X, Ren L, Wan K. Research progress on the effects and mechanisms of different cell types on osteoclast differentiation in bone metabolism in rheumatoid arthritis. Front Med (Lausanne). 2025;12:1643285.","journal-title":"Front Med (Lausanne)"},{"key":"1230_CR18","doi-asserted-by":"publisher","first-page":"7813","DOI":"10.2147\/IJGM.S558927","volume":"18","author":"L Chen","year":"2025","unstructured":"Chen L, Liang L. Osteoimmunology of Osteoporosis in Rheumatoid Arthritis: Emerging Mechanisms and Therapeutic Implications. Int J Gen Med. 2025;18:7813\u201322.","journal-title":"Int J Gen Med"},{"issue":"3","key":"1230_CR19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.4103\/tcmj.tcmj_233_20","volume":"33","author":"CH Peng","year":"2021","unstructured":"Peng CH, Lin WY, Yeh KT, Chen IH, Wu WT, Lin MD. The molecular etiology and treatment of glucocorticoid-induced osteoporosis. Tzu Chi Med J. 2021;33(3):212\u201323.","journal-title":"Tzu Chi Med J"},{"issue":"3","key":"1230_CR20","doi-asserted-by":"publisher","first-page":"E587","DOI":"10.1152\/ajpendo.00219.2016","volume":"311","author":"M Piemontese","year":"2016","unstructured":"Piemontese M, Xiong J, Fujiwara Y, Thostenson JD, O\u2019Brien CA. Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice. Am J Physiol Endocrinol Metab. 2016;311(3):E587\u201393.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"7","key":"1230_CR21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41584-024-01120-w","volume":"20","author":"F Buttgereit","year":"2024","unstructured":"Buttgereit F, Palmowski A, Bond M, Adami G, Dejaco C. Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases. Nat Rev Rheumatol. 2024;20(7):417\u201331.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"1230_CR22","first-page":"79","volume":"43","author":"HKLJ Min","year":"2025","unstructured":"Min HKLJ, Lee SH, Ju JH, Kim HR. Suppressing anti-citrullinated protein antibody-induced osteoclastogenesis in rheumatoid arthritis using anti-CD64 and PAD-2 inhibitors. clin Exp Rheumatol. 2025;43(1):79\u201386.","journal-title":"clin Exp Rheumatol"},{"issue":"2","key":"1230_CR23","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s12276-025-01401-8","volume":"57","author":"ES Lee","year":"2025","unstructured":"Lee ES, Kim HJ, Lee D, Kang JY, Shin DM, Hong JH. Rheumatoid arthritis severity is mediated by crosstalk between synoviocytes and mature osteoclasts through a calcium and cytokine feedback loop. Exp Mol Med. 2025;57(2):402\u201319.","journal-title":"Exp Mol Med"},{"issue":"10","key":"1230_CR24","doi-asserted-by":"publisher","first-page":"e47939","DOI":"10.1097\/MD.0000000000047939","volume":"105","author":"Y Zhong","year":"2026","unstructured":"Zhong Y, Yang F, Chen W. Genetically predicted inflammatory cytokines and bone health outcomes: A 2-sample Mendelian randomization study. Med (Baltim). 2026;105(10):e47939.","journal-title":"Med (Baltim)"},{"issue":"1","key":"1230_CR25","doi-asserted-by":"publisher","first-page":"e11742","DOI":"10.1002\/acr2.11742","volume":"7","author":"JM Scheffler","year":"2025","unstructured":"Scheffler JM, Drevinge C, Lindholm C, Gjertsson I, Lend K, Lund Hetland M, et al. Circulating Baseline CXCR3(+)Th2 and Th17 Cell Proportions Correlate With Trabecular Bone Loss After 48 Weeks of Biological Treatment in Early Rheumatoid Arthritis. ACR Open Rheumatol. 2025;7(1):e11742.","journal-title":"ACR Open Rheumatol"},{"key":"1230_CR26","unstructured":"Nicholas C. Harvey1, *, Emmanuel Biver3,*, Jean-Marc Kaufman4, Jurgen Bauer5, Jaime Branco6, Maria Luisa Brandi7, Olivier Bruyere8, Veronique Coxam9, 10, Alfonso CruzJentoft11, Edward Czerwinski12, Hans Dimai13, Patrice Fardellone14, Francesco Landi15, Jean-Yves Reginster16, Bess Dawson-Hughes17, John A Kanis18, 19, Rene Rizzoli3, +, and Cyrus Cooper1, 2, 20, +. The role of calcium supplementation in healthy musculoskeletal ageing: An Experts consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO) and the International Foundation for Osteoporosis (IOF). Osteoporos Int. 2017."},{"issue":"1","key":"1230_CR27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13075-025-03544-5","volume":"27","author":"Y Shao","year":"2025","unstructured":"Shao Y, Yang Y, Yang X, Xu Z, Zhang H, Li N, et al. A diagnostic model for assessing the risk of osteoporosis in patients with rheumatoid arthritis based on bone turnover markers. Arthritis Res Ther. 2025;27(1):75.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"1230_CR28","doi-asserted-by":"publisher","first-page":"046107","DOI":"10.1063\/5.0233961","volume":"8","author":"HJ Lo","year":"2024","unstructured":"Lo HJ, Tsai CH, Huang TW. Apoptosis-associated genetic mechanisms in the transition from rheumatoid arthritis to osteoporosis: A bioinformatics and functional analysis approach. APL Bioeng. 2024;8(4):046107.","journal-title":"APL Bioeng"},{"issue":"3","key":"1230_CR29","doi-asserted-by":"publisher","first-page":"e41248","DOI":"10.1097\/MD.0000000000041248","volume":"104","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Weng Q, Deng Z, Zhang H, Dai J, Chen X. Rheumatoid arthritis and the risk of fracture: A Mendelian randomization study. Med (Baltim). 2025;104(3):e41248.","journal-title":"Med (Baltim)"},{"key":"1230_CR30","doi-asserted-by":"publisher","first-page":"1759720X2514128","DOI":"10.1177\/1759720X251412846","volume":"18","author":"L Qiu","year":"2026","unstructured":"Qiu L, Zhang W, Tan Z, Wu X, Wang Y, Tang M, et al. Investigating the relationship between osteoporosis and rheumatoid arthritis: prospective cohort study and genetic analyses. Ther Adv Musculoskelet Dis. 2026;18:1759720X251412846.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"4","key":"1230_CR31","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00774-025-01598-8","volume":"43","author":"T Furuya","year":"2025","unstructured":"Furuya T, Inoue E, Yamanaka H, Harigai M, Tanaka E. Increasing fracture incidence over 13 years in patients with rheumatoid arthritis from the IORRA cohort. J Bone Min Metab. 2025;43(4):411\u20138.","journal-title":"J Bone Min Metab"},{"key":"1230_CR32","doi-asserted-by":"publisher","first-page":"116654","DOI":"10.1016\/j.bone.2022.116654","volume":"168","author":"C Gomez-Vaquero","year":"2023","unstructured":"Gomez-Vaquero C, Hernandez JL, Olmos JM, Cerda D, Calleja CH, Lopez JAM, et al. High incidence of clinical fragility fractures in postmenopausal women with rheumatoid arthritis. A case-control study. Bone. 2023;168:116654.","journal-title":"Bone"},{"issue":"1","key":"1230_CR33","doi-asserted-by":"publisher","first-page":"e003919","DOI":"10.1136\/rmdopen-2023-003919","volume":"10","author":"I Tronstad","year":"2024","unstructured":"Tronstad I, Hoff M, Horn J, Vikjord SAA, Videm V, Johansson J, et al. Rheumatoid arthritis, disease-modifying antirheumatic drugs and risk of major osteoporotic fracture: prospective data from the HUNT Study, Norway. RMD Open. 2024;10(1):e003919.","journal-title":"RMD Open"},{"issue":"3","key":"1230_CR34","doi-asserted-by":"publisher","first-page":"rkad091","DOI":"10.1093\/rap\/rkad091","volume":"7","author":"M Ebrahimiarjestan","year":"2023","unstructured":"Ebrahimiarjestan M, Yang L, Wang EE, Carey T, Whelan JJ. Bone mineral density and fractures in patients with rheumatoid arthritis: the DXA-HIP project. Rheumatol Adv Pract. 2023;7(3):rkad091.","journal-title":"Rheumatol Adv Pract"},{"issue":"3","key":"1230_CR35","doi-asserted-by":"publisher","first-page":"e004564","DOI":"10.1136\/rmdopen-2024-004564","volume":"10","author":"P Oelzner","year":"2024","unstructured":"Oelzner P, Mueller PH, Hoffmann T, Schwabe A, Lehmann G, Eidner T, et al. Significant decrease of osteoporosis and osteoporotic fractures in rheumatoid arthritis within a period of 24 years: experiences of a single centre. RMD Open. 2024;10(3):e004564.","journal-title":"RMD Open"},{"key":"1230_CR36","doi-asserted-by":"publisher","unstructured":"Aritomi T, Sonomoto K, Nakayamada S, Tanaka H, Nagayasu A, Kubo S, et al. Biologic and targeted synthetic disease-modifying antirheumatic drugs do not arrest bone loss in patients with rheumatoid arthritis: a long-term multicenter observational study. Arthritis Rheumatol. 2026. https:\/\/doi.org\/10.1002\/art.70125","DOI":"10.1002\/art.70125"},{"issue":"117812","key":"1230_CR37","doi-asserted-by":"publisher","first-page":"117812","DOI":"10.1016\/j.bone.2026.117812","volume":"206","author":"O Taylor-Williams","year":"2026","unstructured":"Taylor-Williams O, Godwin R, Carvallio R, Taylor-Williams M, Barrett C, Inderjeeth C. Bone mineral density in rheumatoid arthritis patients on antirheumatic therapies: a systematic review. Bone. 2026;206(117812):117812.","journal-title":"Bone"},{"issue":"6","key":"1230_CR38","doi-asserted-by":"publisher","first-page":"e70204","DOI":"10.1111\/1756-185X.70204","volume":"28","author":"H Wang","year":"2025","unstructured":"Wang H, Lee Y-H, Cheng IH, Wang S-I, Ji J, Huo A-P, et al. Comparative effectiveness of TNF-\u03b1 and IL-6 inhibitors on bone health outcomes and mortality in Rheumatoid Arthritis patients: A retrospective cohort study. Int J Rheum Dis. 2025;28(6):e70204.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"1230_CR39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s41232-023-00293-3","volume":"43","author":"M Komagamine","year":"2023","unstructured":"Komagamine M, Komatsu N, Ling R, Okamoto K, Tianshu S, Matsuda K, et al. Effect of JAK inhibitors on the three forms of bone damage in autoimmune arthritis: joint erosion, periarticular osteopenia, and systemic bone loss. Inflamm Regen. 2023;43(1):44.","journal-title":"Inflamm Regen"},{"issue":"1","key":"1230_CR40","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00223-025-01410-9","volume":"116","author":"N Schulz","year":"2025","unstructured":"Schulz N, Asendorf T, van Wijnen P, Wilhelmi T, M\u00fcller-Ladner U, Lange U, et al. Bone mineral density during treatment with the Janus kinase inhibitor baricitinib in patients with rheumatoid arthritis: A monocentric observational study. Calcif Tissue Int. 2025;116(1):101.","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"1230_CR41","doi-asserted-by":"publisher","first-page":"e006615","DOI":"10.1136\/rmdopen-2025-006615","volume":"12","author":"A Palmowski","year":"2026","unstructured":"Palmowski A, Haugegaard T, Hafstrom I, Bliddal H, Oldenkott J, Wassenberg S, et al. Changes in bone mineral density and fractures during 2 years of low-dose glucocorticoid treatment for rheumatoid arthritis: a systematic literature review and individual participant data meta-analysis. RMD Open. 2026;12(2):e006615.","journal-title":"RMD Open"},{"issue":"11","key":"1230_CR42","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.3390\/nu12113571","volume":"12","author":"MN Olsen","year":"2020","unstructured":"Olsen MN, Tangvik RJ, Halse AK. Evaluation of nutritional status and methods to identify nutritional risk in rheumatoid arthritis and spondyloarthritis. Nutrients. 2020;12(11):3571.","journal-title":"Nutrients"},{"issue":"13","key":"1230_CR43","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.3390\/nu17132186","volume":"17","author":"JM Nolla","year":"2025","unstructured":"Nolla JM, Moragues C, Valencia-Muntal\u00e0 L, de Daniel-Bisbe L, Berbel-Arcob\u00e9 L, Benavent D, et al. Malnutrition and osteosarcopenia in elderly women with rheumatoid arthritis: A dual clinical perspective. Nutrients. 2025;17(13):2186.","journal-title":"Nutrients"},{"issue":"3","key":"1230_CR44","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40618-023-02219-9","volume":"47","author":"M Schini","year":"2024","unstructured":"Schini M, Johansson H, Harvey NC, Lorentzon M, Kanis JA, McCloskey EV. An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis. J Endocrinol Invest. 2024;47(3):501\u201311.","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"1230_CR45","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00198-025-07397-1","volume":"36","author":"JA Kanis","year":"2025","unstructured":"Kanis JA, Johansson H, McCloskey EV, Liu E, Schini M, Vandenput L, et al. Rheumatoid arthritis and subsequent fracture risk: an individual person meta-analysis to update FRAX. Osteoporos Int. 2025;36(4):653\u201371.","journal-title":"Osteoporos Int"},{"issue":"3","key":"1230_CR46","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00198-010-1524-7","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;22(3):809\u201316.","journal-title":"Osteoporos Int"},{"issue":"1","key":"1230_CR47","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1093\/rheumatology\/kead676","volume":"64","author":"C Richards","year":"2025","unstructured":"Richards C, Stevens R, Lix LM, McCloskey EV, Johansson H, Harvey NC, et al. Fracture prediction in rheumatoid arthritis: validation of FRAX with bone mineral density for incident major osteoporotic fractures. Rheumatology (Oxford). 2025;64(1):228\u201334.","journal-title":"Rheumatology (Oxford)"},{"key":"1230_CR48","doi-asserted-by":"crossref","unstructured":"Elam RE, Li J, Paul A, Kersey E, Schmajuk G, Leslie WD, et al. Performance of U.S.- FRAX TM by race and ethnicity for short-term hip and major osteoporotic fracture prediction in U.S. women with rheumatoid arthritis. J Bone Min Res. 2026 Feb 17:zjag033","DOI":"10.1093\/jbmr\/zjag033"},{"issue":"2","key":"1230_CR49","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3390\/jcm15020491","volume":"15","author":"M Doussiere","year":"2026","unstructured":"Doussiere M, Aboud A, Dequen G, Go\u00ebb V. Artificial intelligence in rheumatology: From algorithms to clinical impact in osteoporosis and chronic inflammatory rheumatic diseases. J Clin Med. 2026;15(2):491.","journal-title":"J Clin Med"},{"issue":"11","key":"1230_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2024.0341","volume":"85","author":"F Kirkham-Wilson","year":"2024","unstructured":"Kirkham-Wilson F, Dennison E. Osteoporosis and Rheumatoid Arthritis: A Review of Current Understanding and Practice. Br J Hosp Med (Lond). 2024;85(11):1\u201311.","journal-title":"Br J Hosp Med (Lond)"},{"issue":"6","key":"1230_CR51","doi-asserted-by":"publisher","first-page":"565","DOI":"10.7861\/clinmed.20.6.rabh","volume":"20","author":"S Ashai","year":"2020","unstructured":"Ashai S, Harvey NC. Rheumatoid arthritis and bone health. Clin Med (Lond). 2020;20(6):565\u20137.","journal-title":"Clin Med (Lond)"},{"issue":"12","key":"1230_CR52","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s40266-019-00714-4","volume":"36","author":"HG Raterman","year":"2019","unstructured":"Raterman HG, Lems WF. Pharmacological Management of Osteoporosis in Rheumatoid Arthritis Patients: A Review of the Literature and Practical Guide. Drugs Aging. 2019;36(12):1061\u201372.","journal-title":"Drugs Aging"},{"issue":"10","key":"1230_CR53","first-page":"CD001347","volume":"10","author":"CS Allen","year":"2016","unstructured":"Allen CS, Yeung JH, Vandermeer B, Homik J. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev. 2016;10(10):CD001347.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1230_CR54","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/s00198-005-0037-2","volume":"17","author":"WF Lems","year":"2006","unstructured":"Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporos Int. 2006;17(5):716\u201323.","journal-title":"Osteoporos Int"},{"key":"1230_CR55","doi-asserted-by":"publisher","first-page":"867610","DOI":"10.3389\/fendo.2022.867610","volume":"13","author":"H Huang","year":"2022","unstructured":"Huang H, Wang Y, Xie W, Geng Y, Gao D, Zhang Z. Impact of Treat-to-Target Therapy on Bone Mineral Density Loss in Patients With Rheumatoid Arthritis: A Prospective Cohort Study. Front Endocrinol (Lausanne). 2022;13:867610.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"1230_CR56","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00774-022-01323-9","volume":"40","author":"M Takahata","year":"2022","unstructured":"Takahata M, Shimizu T, Yamada S, Yamamoto T, Hasegawa T, Fujita R, et al. Bone biopsy findings in patients receiving long-term bisphosphonate therapy for glucocorticoid-induced osteoporosis. J Bone Min Metab. 2022;40(4):613\u201322.","journal-title":"J Bone Min Metab"},{"issue":"8","key":"1230_CR57","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"20","author":"SRSMJ Cummings","year":"2009","unstructured":"Cummings SRSMJ, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. N Engl J Med. 2009;20(8):756\u201365.","journal-title":"N Engl J Med"},{"issue":"5","key":"1230_CR58","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1210\/jc.2018-02236","volume":"104","author":"H Lyu","year":"2019","unstructured":"Lyu H, Jundi B, Xu C, Tedeschi SK, Yoshida K, Zhao S, et al. Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. J Clin Endocrinol Metab. 2019;104(5):1753\u201365.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1230_CR59","doi-asserted-by":"publisher","first-page":"rkab099","DOI":"10.1093\/rap\/rkab099","volume":"5","author":"M Yagita","year":"2021","unstructured":"Yagita M, Morita T, Kumanogoh A. Therapeutic efficacy of denosumab for rheumatoid arthritis: a systematic review and meta-analysis. Rheumatol Adv Pract. 2021;5(3):rkab099.","journal-title":"Rheumatol Adv Pract"},{"issue":"3","key":"1230_CR60","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/biomedicines13030732","volume":"13","author":"YT Hung","year":"2025","unstructured":"Hung YT, Wu WT, Lee RP, Yao TK, Yeh KT. Beyond bone remodeling: denosumab\u2019s multisystemic benefits in musculoskeletal health, metabolism, and age-related diseases-a narrative review. Biomedicines. 2025;13(3):732.","journal-title":"Biomedicines"},{"key":"1230_CR61","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"R Steven","year":"2018","unstructured":"Steven R, Cummings SF. 2 Richard Eastell,3 Nigel Gilchrist,4 Jens-Erik Beck Jensen,5 Michael McClung,6 Christian Roux,7 Ove T\u20acorring,8 Ivo Valter,9 Andrea T Wang,10, Brown11 aJP. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. JBMR. 2018;33:190\u20138.","journal-title":"JBMR"},{"issue":"16","key":"1230_CR62","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016;375(16):1532\u201343.","journal-title":"N Engl J Med"},{"issue":"5","key":"1230_CR63","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00198-024-07019-2","volume":"35","author":"K Ebina","year":"2024","unstructured":"Ebina K, Nagayama Y, Kashii M, Tsuboi H, Okamura G, Miyama A, et al. An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case-control study. Osteoporos Int. 2024;35(5):841\u20139.","journal-title":"Osteoporos Int"},{"issue":"3","key":"1230_CR64","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.afos.2021.08.001","volume":"7","author":"T Mochizuki","year":"2021","unstructured":"Mochizuki T, Yano K, Ikari K, Okazaki K. Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: An open-label, randomized, pilot study. Osteoporos Sarcopenia. 2021;7(3):110\u20134.","journal-title":"Osteoporos Sarcopenia"},{"issue":"15","key":"1230_CR65","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017;377(15):1417\u201327.","journal-title":"N Engl J Med"},{"issue":"3","key":"1230_CR66","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1177\/1759720X16643340","volume":"8","author":"T Zegkos","year":"2016","unstructured":"Zegkos T, Kitas G, Dimitroulas T. Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps. Ther Adv Musculoskelet Dis. 2016;8(3):86\u2013101.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1230_CR67","doi-asserted-by":"publisher","first-page":"1336075","DOI":"10.3389\/fphar.2024.1336075","volume":"15","author":"L Dong","year":"2024","unstructured":"Dong L, Jiang L, Xu Z, Zhang X. Denosumab, teriparatide and bisphosphonates for glucocorticoid-induced osteoporosis: a Bayesian network meta-analysis. Front Pharmacol. 2024;15:1336075.","journal-title":"Front Pharmacol"},{"issue":"11","key":"1230_CR68","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1002\/art.24879","volume":"60","author":"KG Saag","year":"2009","unstructured":"Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346\u201355.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"1230_CR69","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1002\/art.42646","volume":"75","author":"MB Humphrey","year":"2023","unstructured":"Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2023;75(12):2088\u2013102.","journal-title":"Arthritis Rheumatol"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-026-01230-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-026-01230-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-026-01230-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:03:20Z","timestamp":1786511000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-026-01230-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1230"],"URL":"https:\/\/doi.org\/10.1007\/s11926-026-01230-2","relation":{},"ISSN":["1534-6307"],"issn-type":[{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"15 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ED had received travel support from Fresenius Kabi, Promedius Inc funding for focus group study and previous involvement with Viatris, UCB, Lilly, Amgen. FL received lecture fees from Alfasigma.","order":2,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","label":"Human and Animal Rights","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any information derived from a particular individual.","order":4,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24"}}